Boost for Indian pharma
"The next two years are likely to be exciting for Indian pharma's generic business. The companies that have plenty of registrations such as DRL, Cipla, and Ranbaxy would remain at the forefront," said Deven Choksey, MD of KR Choksey Sec.
